Legare, MD, J. M. Once-Weekly TransCon CNP (navepegritide) in Children With Achondroplasia (ACcomplisH): A Phase 2, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Trial.
Savarirayan, R., Hoernschemeyer, D. G., Ljungberg, M., Zarate, Y. A., Bacino, C. A., Bober, M. B., Legare, J. M., Högler, W., Quattrin, T., Abuzzahab, M. J., Hofman, P. L., White, K. K., Ma, N. S., Schnabel, D., Sousa, S. B., Mao, M., Smith, A., Chakraborty, M., Giwa, A., Winding, B., … McDonnell, C. (2023). Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial. EClinicalMedicine, 65, 102258. https://doi.org/10.1016/j.eclinm.2023.102258